FGFR2 Inhibitor Nabs Speedy Approval for Cholangiocarcinoma
The FDA granted accelerated approval to futibatinib (Lytgobi) tablets for treating adults…
Browsing Tag
FGFR2
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly…
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4)…